[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Testicular Cancer Drugs Market Report 2017

August 2017 | 99 pages | ID: U636C88DE2EEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Testicular Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Testicular Cancer Drugs in these regions, from 2012 to 2022 (forecast).
United States Testicular Cancer Drugs market competition by top manufacturers/players, with Testicular Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Bristol-Myers Squibb
  • Hospira
  • Ovation Pharmaceuticals
  • Teva Pharmaceutical
  • ZIOPHARM Oncology
  • Fresenius Kabi
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Cisplatin
  • Etoposide
  • Ifosfamide
  • Paclitaxel
  • Vinblastine
  • Bleomycin
  • Dactinomycin
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Testicular Cancer Drugs for each application, including
  • Seminomas
  • Non-Seminomas
  • Leydig Cell Cancer
  • Sertoli Cell Cancer
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Testicular Cancer Drugs Market Report 2017

1 TESTICULAR CANCER DRUGS OVERVIEW

1.1 Product Overview and Scope of Testicular Cancer Drugs
1.2 Classification of Testicular Cancer Drugs by Product Category
  1.2.1 United States Testicular Cancer Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Testicular Cancer Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Cisplatin
  1.2.4 Etoposide
  1.2.5 Ifosfamide
  1.2.6 Paclitaxel
  1.2.7 Vinblastine
  1.2.8 Bleomycin
  1.2.9 Dactinomycin
1.3 United States Testicular Cancer Drugs Market by Application/End Users
  1.3.1 United States Testicular Cancer Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Seminomas
  1.3.3 Non-Seminomas
  1.3.4 Leydig Cell Cancer
  1.3.5 Sertoli Cell Cancer
1.4 United States Testicular Cancer Drugs Market by Region
  1.4.1 United States Testicular Cancer Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Testicular Cancer Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Testicular Cancer Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Testicular Cancer Drugs Status and Prospect (2012-2022)
  1.4.5 New England Testicular Cancer Drugs Status and Prospect (2012-2022)
  1.4.6 The South Testicular Cancer Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Testicular Cancer Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Testicular Cancer Drugs (2012-2022)
  1.5.1 United States Testicular Cancer Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Testicular Cancer Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES TESTICULAR CANCER DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Testicular Cancer Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Testicular Cancer Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Testicular Cancer Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Testicular Cancer Drugs Market Competitive Situation and Trends
  2.4.1 United States Testicular Cancer Drugs Market Concentration Rate
  2.4.2 United States Testicular Cancer Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Testicular Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES TESTICULAR CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Testicular Cancer Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Testicular Cancer Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Testicular Cancer Drugs Price by Region (2012-2017)

4 UNITED STATES TESTICULAR CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Testicular Cancer Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Testicular Cancer Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Testicular Cancer Drugs Price by Type (2012-2017)
4.4 United States Testicular Cancer Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES TESTICULAR CANCER DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Testicular Cancer Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Testicular Cancer Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES TESTICULAR CANCER DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Bristol-Myers Squibb
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bristol-Myers Squibb Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Hospira
  6.2.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Hospira Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Ovation Pharmaceuticals
  6.3.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Ovation Pharmaceuticals Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Teva Pharmaceutical
  6.4.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Teva Pharmaceutical Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 ZIOPHARM Oncology
  6.5.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 ZIOPHARM Oncology Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Fresenius Kabi
  6.6.2 Testicular Cancer Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Fresenius Kabi Testicular Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview

7 TESTICULAR CANCER DRUGS MANUFACTURING COST ANALYSIS

7.1 Testicular Cancer Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Testicular Cancer Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Testicular Cancer Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Testicular Cancer Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES TESTICULAR CANCER DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Testicular Cancer Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Testicular Cancer Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Testicular Cancer Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Testicular Cancer Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Testicular Cancer Drugs
Figure United States Testicular Cancer Drugs Market Size (K Pcs) by Type (2012-2022)
Figure United States Testicular Cancer Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Cisplatin Product Picture
Figure Etoposide Product Picture
Figure Ifosfamide Product Picture
Figure Paclitaxel Product Picture
Figure Vinblastine Product Picture
Figure Bleomycin Product Picture
Figure Dactinomycin Product Picture
Figure United States Testicular Cancer Drugs Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Testicular Cancer Drugs by Application in 2016
Figure Seminomas Examples
Table Key Downstream Customer in Seminomas
Figure Non-Seminomas Examples
Table Key Downstream Customer in Non-Seminomas
Figure Leydig Cell Cancer Examples
Table Key Downstream Customer in Leydig Cell Cancer
Figure Sertoli Cell Cancer Examples
Table Key Downstream Customer in Sertoli Cell Cancer
Figure United States Testicular Cancer Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Testicular Cancer Drugs Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Testicular Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Testicular Cancer Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Testicular Cancer Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Testicular Cancer Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Testicular Cancer Drugs Sales Share by Players/Suppliers
Figure 2017 United States Testicular Cancer Drugs Sales Share by Players/Suppliers
Figure United States Testicular Cancer Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Testicular Cancer Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Testicular Cancer Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Testicular Cancer Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Testicular Cancer Drugs Revenue Share by Players/Suppliers
Table United States Market Testicular Cancer Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Testicular Cancer Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Testicular Cancer Drugs Market Share of Top 3 Players/Suppliers
Figure United States Testicular Cancer Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Testicular Cancer Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Testicular Cancer Drugs Product Category
Table United States Testicular Cancer Drugs Sales (K Pcs) by Region (2012-2017)
Table United States Testicular Cancer Drugs Sales Share by Region (2012-2017)
Figure United States Testicular Cancer Drugs Sales Share by Region (2012-2017)
Figure United States Testicular Cancer Drugs Sales Market Share by Region in 2016
Table United States Testicular Cancer Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Testicular Cancer Drugs Revenue Share by Region (2012-2017)
Figure United States Testicular Cancer Drugs Revenue Market Share by Region (2012-2017)
Figure United States Testicular Cancer Drugs Revenue Market Share by Region in 2016
Table United States Testicular Cancer Drugs Price (USD/Pcs) by Region (2012-2017)
Table United States Testicular Cancer Drugs Sales (K Pcs) by Type (2012-2017)
Table United States Testicular Cancer Drugs Sales Share by Type (2012-2017)
Figure United States Testicular Cancer Drugs Sales Share by Type (2012-2017)
Figure United States Testicular Cancer Drugs Sales Market Share by Type in 2016
Table United States Testicular Cancer Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Testicular Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Testicular Cancer Drugs by Type (2012-2017)
Figure Revenue Market Share of Testicular Cancer Drugs by Type in 2016
Table United States Testicular Cancer Drugs Price (USD/Pcs) by Types (2012-2017)
Figure United States Testicular Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table United States Testicular Cancer Drugs Sales (K Pcs) by Application (2012-2017)
Table United States Testicular Cancer Drugs Sales Market Share by Application (2012-2017)
Figure United States Testicular Cancer Drugs Sales Market Share by Application (2012-2017)
Figure United States Testicular Cancer Drugs Sales Market Share by Application in 2016
Table United States Testicular Cancer Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Testicular Cancer Drugs Sales Growth Rate by Application (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Hospira Basic Information List
Table Hospira Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Hospira Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure Hospira Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Hospira Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Ovation Pharmaceuticals Basic Information List
Table Ovation Pharmaceuticals Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Ovation Pharmaceuticals Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure Ovation Pharmaceuticals Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Ovation Pharmaceuticals Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceutical Basic Information List
Table Teva Pharmaceutical Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure Teva Pharmaceutical Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Teva Pharmaceutical Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table ZIOPHARM Oncology Basic Information List
Table ZIOPHARM Oncology Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure ZIOPHARM Oncology Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure ZIOPHARM Oncology Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure ZIOPHARM Oncology Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Fresenius Kabi Basic Information List
Table Fresenius Kabi Testicular Cancer Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Fresenius Kabi Testicular Cancer Drugs Sales Growth Rate (2012-2017)
Figure Fresenius Kabi Testicular Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Fresenius Kabi Testicular Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Testicular Cancer Drugs
Figure Manufacturing Process Analysis of Testicular Cancer Drugs
Figure Testicular Cancer Drugs Industrial Chain Analysis
Table Raw Materials Sources of Testicular Cancer Drugs Major Players/Suppliers in 2016
Table Major Buyers of Testicular Cancer Drugs
Table Distributors/Traders List
Figure United States Testicular Cancer Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Testicular Cancer Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Testicular Cancer Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Testicular Cancer Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Testicular Cancer Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Testicular Cancer Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories